Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05462639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ELRANATAMAB (PF-06863135) MONOTHERAPY EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity. This expanded access protocol will provide access to elranatamab until it becomes commercially accessible to patients who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody and have no access to other comparable/alternative therapy and for whom elranatamab could be a possible treatment option.
Study identification
- NCT ID
- NCT05462639
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Aug 9, 2024
United States locations
- U.S. sites
- 33
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| UCLA Hematology/Oncology - Westwood (Building 200 Suite 120) | Los Angeles | California | 90095 | — |
| UC Irvine Health | Orange | California | 92868 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| Baptist Hospital of Miami | Miami | Florida | 33176 | — |
| Miami Cancer Institute | Miami | Florida | 33176 | — |
| Memorial Cancer Institute at Memorial Hospital West | Pembroke Pines | Florida | 33021 | — |
| Memorial Cancer Institute at Memorial Hospital West | Pembroke Pines | Florida | 33026 | — |
| Memorial Cancer Institute at Memorial Hospital West | Pembroke Pines | Florida | 33028 | — |
| Memorial Hospital West Laboratory Services | Pembroke Pines | Florida | 33028 | — |
| Blood and Marrow Transplant Group of Georgia | Atlanta | Georgia | 30342 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Georgia Cancer Center at Augusta University | Augusta | Georgia | 30912 | — |
| Franciscan Health | Indianapolis | Indiana | 46237 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39213 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| MSK Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| MSK Monmouth | Middletown | New Jersey | 07748 | — |
| MSK Bergen | Montvale | New Jersey | 07645 | — |
| MSK Commack | Commack | New York | 11725 | — |
| MSK Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center | Long Island City | New York | 11101 | — |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| MSK Nassau | Uniondale | New York | 11553 | — |
| OhioHealth Arthur G.H. Bing, MD Cancer Center | Columbus | Ohio | 43214 | — |
| OhioHealth Research Institute | Columbus | Ohio | 43214 | — |
| Baylor Scott & White Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy | Dallas | Texas | 75246 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Texas Oncology | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05462639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05462639 live on ClinicalTrials.gov.